The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism

Drug Metabolism and Disposition

Volumn 35, Issue 10, 2007, Pages 1926-1934

  Aimová, Dagmar ^a   Svobodová, Lucie ^a   Kotrbová, Věra ^a   Mrázová, Barbora ^a   Hodek, Petr ^a   Hudeček, Jiří ^a   Václavíková, Radka ^c   Frei, Eva ^b   Stiborová, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYELLIPTICINE; 13 HYDROXYELLIPTICINE; 7 HYDROXYELLIPTICINE; 9 HYDROELLIPTICINE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG METABOLITE; ELLIPTICINE; PEROXIDASE; PHOSPHORUS 32; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DNA ADDUCT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; ISOTOPE LABELING; MALE; MEASUREMENT; MICROSOME; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DNA ADDUCTS; ELLIPTICINES; ENZYME INDUCTION; FEMALE; KIDNEY; LIVER; LUNG; MALE; MICROSOMES; RATS; RATS, WISTAR; RNA, MESSENGER;

RATTUS;

EID: 34748888569     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016048     Document Type: Article

References (40)

1. Aimová D and Stiborová M (2005) Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450. Biomed Pap 149:437-440.
2. Auclair C (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259:1-14.
3. Boogaard AT, Pandit UK, and Koomen GJ (1994) Ring-D modifications of ellipticine. 2. Chlorination of ellipticine via its N-oxide and synthesis and selective acetylation of 5,6,11-trimethyl-5H benzo[B]carbazole. Tetrahedron 50:4811-4828.
4. Bořek-Dohalská L, Frei E, and Stiborová M (2004) DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69:603-615.
5. Chang C-Y and Puga A (1998) Constitutive activation of the aromatic hydrocarbon receptor. Mol Cell Biol 18:525-535.
6. Chen RM, Chou MW, and Ueng TH (1998) Induction of cytochrome P450 1A in hamster liver and lung by 6-nitrochrysene. Arch Toxicol 72:395-401.
7. Couture LA, Abbott BD, and Birnbaum LS (1990) A critical review of the developmental toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin: recent advances towards understanding the mechanism. Teratology 42:619-627.
8. Cresteil T, Le Provost E, Leroux JP, and Lesca P (1982) Enzymatic and immunological characterization of cytochromes P 450 from ellipticine-treated rat liver. Biochem Biophys Res Commun 107:1037-1045.
9. Degawa M, Nakayama M, Konno Y, Masubuchi K, and Yamazoe Y (1998) 2-Methoxy-4-nitroaniline and its isomers induce cytochrome P450 1A (CYP1A) enzymes with different selectivities in the rat livers. Biochim Biophys Acta 1379:391-398.
10. Dickins M (2004) Induction of cytochromes P450. Curr Top Med Chem 4:1745-1766.
11. Fernandez N, Roy M, and Lesca P (1988) Binding characteristics of Ah receptors from rats and mice before and after separation from hepatic cytosols. 7-Hydroxyellipticine as a competitive antagonist of cytochrome P-450 induction. Eur J Biochem 172:585-592.
12. Fossé P, René B, Charra M, Paoletti C, and Saucier JM (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42:590-595.
13. Frei E, Bieler CA, Arlt VM, Wiessler M, and Stiborová M (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64:289-295.
14. Froelich-Ammon SJ, Patchan MW, Osheroff N, and Thompson RB (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 270:14998-15004.
15. Gasiewicz TA, Kende RS, Rucci G, Whitney B, and Willey JJ (1996) Analysis of structural requirements for Ah receptor antagonist activity: ellipticines, flavones, and related compounds. Biochem Pharmacol 52:1787-1830.
16. Guengerich FP and Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol 4:391-407.
17. Iba MM, Fung J, Thomas PE, and Park Y (1999) Constitutive and induced expression by pyridine and β-naphthoflavone of rat CYP1A is sexually dimorphic. Arch Toxicol 73:208-216.
18. Ivy SP, Tulpule A, Fairchild CR, Averbuch SD, Myers CE, Nebert DW, Baird WM, and Cowan KH (1988) Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J Biol Chem 263:19119-19125.
19. Kerzee JK and Ramos KS (2001) Constitutive and inducible expression of Cyp1a1 and Cyp1b1 in vascular smooth muscle cells. Circ Res 89:573-582.
20. Kotrbová V, Aimová D, Bøezinová A, Janouchová K, Poljaková J, Hodek P, Frei E, and Stiborová M (2006) Cytochromes P450 reconstituted with NADPH:P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. Neuro Endocrinol Lett 27 (Suppl 2):18-20.
21. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
22. Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hrabìta J, and Stiborová M (2007) DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett 252:270-279.
23. Rendic S and DiCarlo FJ (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-480.
24. Rekha GK and Sladek NE (1997) Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother Pharmacol 40:215-224.
25. Schwaller MA, Allard B, Lescot E, and Moreau F (1995) Protonophoric activity of ellipticine and isomers across the energy-transducing membrane of mitochondria. J Biol Chem 270:22709-22713.
26. Shehin SE, Stephenson RO, and Greenleee WF (2000) Transcriptional regulation of the human CYP1B1 gene: evidence for involvement of an aryl hydrocarbon receptor response element in the constitutive expression. J Biol Chem 275:6770-6775.
27. Singh MP, Hill GC, Peoch D, Rayner B, Inabach JL, and Lown JW (1994) High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33:10271-10285.
28. Stiborová M, Bieler CA, Wiessler M, and Frei E (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62:1675-1684.
29. Stiborová M, Bořek-Dohalská L, Hodek P, Mráz J, and Frei E (2002a) New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch Biochem Biophys 403:41-49.
30. 32P-postlabeling. Int J Cancer 107:885-890.
31. Stiborová M, Dračínská H, Hájková J, Kadeřábková P, Frei E, Schmeiser HH, Souček P, Phillips DH, and Arlt VM (2006) The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and -1A2 and NAD(P)H:quinone oxidoreductase. Drug Metab Dispos 34:1398-1405.
32. Stiborová M, Frei E, Sopko B, Sopková K, Marková V, Laňková M, Kumstýřová T, Wiessler M, and Schmeiser HH (2003b) Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24:1695-1703.
33. Stiborová M, Martínek V, Rýdlová H, Hodek P, and Frei E (2002b) Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res 62:5678-5684.
34. Stiborová M, Martínek V, Rýdlová H, Koblas T, and Hodek P (2005) Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett 220:145-154.
35. Stiborová M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T, and Frei E (2007) Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer 120:243-251.
36. 2-oxide. Cancer Res 64:8374-8380.
37. Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, and Frei E (2003c) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16:38-47.
38. 1 phase by 9-hydroxyellipticine. Anticancer Res 19:3099-3108.
39. Wiechelman KJ, Braun RD, and Fitzpatrick JD (1988) Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 175:231-237.
40. Wijsmuller WFA, Warner MJ, Koonen GI, and Pandit UK (1986) Pyridocarbazole alkaloids. Synthesis of olivacine and ellipticine analogues. Heterocycles 24:1795-1797.